Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + vopratelimab
- Development stage
- Unknown
- Lead developer
- Concentra Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nivolumab + vopratelimab is an investigational combination therapy for advanced solid tumors. Nivolumab is a fully human IgG4 monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to enhance T-cell mediated antitumor responses. Vopratelimab is a monoclonal antibody agonist of the inducible costimulator (ICOS), designed to activate ICOS signaling on T cells and promote antitumor immunity. The combination aims to synergistically enhance immune activation by both relieving inhibitory signaling (via PD-1 blockade) and providing co-stimulatory signals (via ICOS agonism). Clinical trials have shown that this combination has a favorable safety profile but modest efficacy overall; however, clinical benefit appears enriched in patients with specific pharmacodynamic biomarkers such as emergence of ICOS-high CD4 T cells[1][2][4]. The primary developer of vopratelimab is Jounce Therapeutics.
- Brand names
- Opdivo
- Other names
- ICOS agonist antibody + anti-PD-1 antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ICOS (Inducible T-cell costimulator)
Beyond the preview
Go deeper on nivolumab + vopratelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + vopratelimab.